Amendment to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-10. (Canceled)

11. (Currently amended) A method of preventing influenza, comprising a step of administering to nasal mucosa at least once:

[[A)]] a vaccine at a concentration sufficient to produce secretory IgA, wherein said vaccine comprises:

a) [[a]] an isolated double-stranded RNA;

b) a subunit antigen or inactivated antigen of an influenza virus; and

c) a pharmaceutically acceptable carrier, wherein said carrier is selected from the group consisting of water, an aqueous physiological solution, and an artificial aqueous cerebrospinal fluid.

12. (Original) The method of claim 11, wherein said vaccine is administered at least twice.

13. (Currently Amended) The method of claim [[11]] 12, wherein said vaccine is administered at an interval of at least 1 week or more.

14. (Original) The method of claim 11, wherein said double-stranded RNA comprises Poly(I:C).

Claims 15-22. (Canceled)

23. (New) The method of claim 11 wherein the subunit antigen comprises at least one subunit selected from the group consisting of the influenza virus subunits HA, NA, M1, M2, NP, PB1, PB2, PA and NS2.

24. (New) The method of claim 11 wherein said double-stranded RNA is administered at a concentration of 0.1 to 10 mg/ml per dose.

25. (New) The method of claim 24 wherein said double-stranded RNA is administered at a concentration of 0.5 to 2 mg/ml per dose.

26. (New) The method of claim 11, wherein the size of said double-stranded RNA is 10^2-10^8 bp.

27. (New) The method of claim 25, wherein the size of said double-stranded RNA is 10^2-10^8 bp.

28. (New) The method of claim 23, wherein said subunit comprises at least NA or HA.

29. (New) A method of producing a protective reaction against influenza, comprising a step of administering to nasal mucosa

a vaccine at a concentration sufficient to produce secretory IgA, wherein said vaccine comprises:

a) an adjuvant consisting essentially of double-stranded RNA;

b) an antigen of an influenza virus; and

c) a pharmaceutically acceptable carrier.

30. (New) The method of claim 29 wherein the vaccine is administered at least twice with an interval of 1 to 3 weeks between administrations.

31. (New) The method of claim 29, wherein said double-stranded RNA comprises Poly(I:C).

32. (New) The method of claim 31 wherein the subunit antigen comprises at least one subunit selected from the group consisting of the influenza virus subunits HA, NA, M1, M2, NP, PB1, PB2, PA and NS2.

33. (New) The method of claim 32 wherein said double-stranded RNA is administered at a concentration of 0.1 to 10 mg/ml per dose.

34. (New) The method of claim 33, wherein the size of said double-stranded RNA is 10^2-10^8 bp.